Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 10:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 1,549 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Open Surgery Clear all
Recruiting Phase 2 Interventional

Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer

NCT07276789
View directory record Official record
Conditions
Non Small Cell Lung Cancer (NSCLC)
Interventions
LS301-IT 0.1 mg/kg
Drug
Lead sponsor
Integro Theranostics
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 25, 2026, 10:08 AM EDT
Completed Not applicable Interventional

No Opioids PrescrIptions On Discharge After Surgery

NCT04469868
View directory record Official record
Conditions
Opioid Use, Prescription Drug Abuse and Dependency, Surgery, Postoperative Pain
Interventions
No opioids at discharge
Behavioral
Lead sponsor
Albany Medical College
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 25, 2026, 10:08 AM EDT
Enrolling by invitation No phase listed Observational

5-Year Postoperative Outcomes of Patients Who Completed the CREST Study

NCT07480343
View directory record Official record
Conditions
Open-angle Glaucoma (OAG)
Interventions
CycloPen Micro-Interventional Cyclodialysis System, CycloPen Micro-Interventional Cyclodialysis System Post Cataract
Procedure
Lead sponsor
Iantrek, Inc.
Industry
Eligibility
Not listed
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
10
States / cities
Newport Beach, California • Cape Coral, Florida • DeLand, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 25, 2026, 10:08 AM EDT
Completed Not applicable Interventional

ProSPective Evaluation of Non-contrast sINe spiN Flat-dEtectoR CT for the Detection of Intracranial hemorrhageS

NCT05458908
View directory record Official record
Conditions
Stroke
Interventions
Non-contrast cranial MDCT head scan, Non-contrast syngo DynaCT Sine Spin head scan and application software
Diagnostic Test
Lead sponsor
University Hospital, Basel, Switzerland
Other
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
8
States / cities
Denver, Colorado • Chicago, Illinois • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 25, 2026, 10:08 AM EDT
Completed Phase 1 Interventional

Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer

NCT02605915
View directory record Official record
Conditions
HER2-Positive Metastatic Breast Cancer, HER2-Negative Metastatic Breast Cancer, Locally Advanced or Early Breast Cancer
Interventions
Atezolizumab, Carboplatin, Docetaxel, Pertuzumab, Trastuzumab, Trastuzumab emtansine, Doxorubicin, Cyclophosphamide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
20
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Joliet, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 25, 2026, 10:08 AM EDT
Recruiting Not applicable Interventional

Post-Market Clinical Study of Functional Motion Outcomes in Subjects Treated With the Minuteman Device

NCT06355791
View directory record Official record
Conditions
Degenerative Conditions of the Lumbar Spine, Lumbar Spinal Stenosis, Spondylolisthesis
Interventions
Minuteman G5 Device
Device
Lead sponsor
Spinal Simplicity LLC
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
6
States / cities
Newnan, Georgia • Indianapolis, Indiana • Kansas City, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 25, 2026, 10:08 AM EDT
Terminated Phase 1 Interventional

Stem Cell Injection to Treat Heart Damage During Open Heart Surgery

NCT01557543
View directory record Official record
Conditions
Heart Disease, Ischemic Heart Disease, Coronary Artery Disease, Coronary Artery Disease (CAD)
Interventions
Cell Therapy
Other
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 25, 2026, 10:08 AM EDT
Recruiting Phase 1 Interventional

Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell Carcinoma

NCT07741643
View directory record Official record
Conditions
HNSCC,Larynx, Pharynx and Oral Cavity, Squamous Cell Carcinoma, Head and Neck Cancer, Head and Neck Surgery
Interventions
Panitumumab-IRDye800, [18F]NOTA-ABY-030
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 25, 2026, 10:08 AM EDT
Terminated Not applicable Interventional Results available

Treating Stimulant Addiction With Repetitive Transcranial Magnetic Stimulation

NCT04228276
View directory record Official record
Conditions
Stimulant Use Disorder, Substance-related Disorders
Interventions
Repetitive transcranial magnetic stimulation (rTMS)
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 25, 2026, 10:08 AM EDT
Completed Phase 3 Interventional Results available

Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects

NCT00360568
View directory record Official record
Conditions
Dyskinesias, Parkinson's Disease, Severe Motor Fluctuations
Interventions
Levodopa-carbidopa intestinal gel, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
Drug · Device
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
30 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
16
States / cities
Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2015 · Synced Oct 25, 2026, 10:08 AM EDT
Completed Phase 3 Interventional Results available

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma

NCT01345019
View directory record Official record
Conditions
Cancer, Hematologic Malignancies, Multiple Myeloma, Oncology, Bone Metastases, Multiple Myeloma Bone Lesions
Interventions
Denosumab, Zoledronic acid, Placebo to Denosumab, Placebo to zoledronic acid, Denosumab (for the open-label treatment phase)
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
1,718 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
79
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Anaheim, California + 67 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 25, 2026, 10:08 AM EDT
Completed Not applicable Interventional

Best Endovascular vs. Best Surgical Therapy in Patients With Critical Limb Ischemia

NCT02060630
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
Open surgical revascularization, Endovascular revascularization
Procedure · Device
Lead sponsor
Carelon Research
Other
Eligibility
18 Years and older
Enrollment
1,843 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
144
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 102 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Oct 25, 2026, 10:08 AM EDT
Terminated Phase 1 Interventional

A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma

NCT00585000
View directory record Official record
Conditions
Melanoma
Interventions
CP-675,206
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
8
States / cities
Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Oct 25, 2026, 10:08 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of BIIB111 for the Treatment of Choroideremia

NCT03496012
View directory record Official record
Conditions
Choroideremia
Interventions
BIIB111
Genetic
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older · Male only
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
8
States / cities
Los Angeles, California • Miami, Florida • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Oct 25, 2026, 10:08 AM EDT
Completed No phase listed Observational

Pain and Quality of Life After Retromuscular Ventral Hernia Repair (RECOVER)

NCT04487522
View directory record Official record
Conditions
Ventral Hernia
Interventions
Open retromuscular ventral hernia repair, Laparoscopic retromuscular ventral hernia repair, Robotic-assisted retromuscular ventral hernia repair
Procedure · Device
Lead sponsor
Intuitive Surgical
Industry
Eligibility
18 Years to 89 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Oakland, California • Sacramento, California • Santa Clara, California + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 25, 2026, 10:08 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Development of Adaptive Deep Brain Stimulation for OCD (Phase 1a)

NCT03457675
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Activa PC+S DBS implant for OCD, One Month Blinded Discontinuation Period
Device · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
21 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania • Providence, Rhode Island • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 25, 2026, 10:08 AM EDT
Completed Phase 2 Interventional Results available

Repeat Quadratus Lumborum Block to Reduce Opioid Need in Patients After Pancreatic Surgery

NCT03745794
View directory record Official record
Conditions
Pancreatic Carcinoma
Interventions
Best Practice, Quadratus Lumborum Block, Quality-of-Life Assessment, Questionnaire Administration
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 25, 2026, 10:08 AM EDT
Recruiting Phase 2 Interventional

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

NCT04553770
View directory record Official record
Conditions
Early-stage Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer
Interventions
Anastrozole, Therapeutic Conventional Surgery, Trastuzumab Deruxtecan
Drug · Procedure · Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
9
States / cities
Fullerton, California • Los Alamitos, California • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 25, 2026, 10:08 AM EDT
Terminated Phase 2 Interventional Results available

A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

NCT04832854
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC)
Interventions
Atezolizumab, Tiragolumab, Carboplatin, Cisplatin, Pemetrexed, Gemcitabine, Paclitaxel
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Duarte, California • Los Angeles, California • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 25, 2026, 10:08 AM EDT
Completed No phase listed Observational Results available

Obtain Additional Information on Use of CorMatrix ECM (Extracellular Matrix)

NCT02073331
View directory record Official record
Conditions
Coronary Disease
Interventions
Not listed
Lead sponsor
Elutia Inc.
Industry
Eligibility
Not listed
Enrollment
1,420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
43
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2023 · Synced Oct 25, 2026, 10:08 AM EDT
Not yet recruiting Phase 2 Interventional

Augmentation Cystoplasty Using an Autologous Neo-Bladder Construct

NCT05054790
View directory record Official record
Conditions
Contracted Bladder
Interventions
"Neo-Bladder" Construct
Biological
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 25, 2026, 10:08 AM EDT
Recruiting Phase 3 Interventional

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

NCT04575935
View directory record Official record
Conditions
Advanced Ovarian Carcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Tumor, Fallopian Tube Serous Neoplasm, Fallopian Tube Transitional Cell Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Stage IIIC Fallopian Tube Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8
Interventions
Chemotherapy, Laparotomy, Minimally Invasive Surgery, Quality-of-Life Assessment, Questionnaire Administration
Drug · Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
13
States / cities
Miami, Florida • Weston, Florida • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 25, 2026, 10:08 AM EDT
Not listed Not applicable Interventional

Medial Versus Traditional Approach to US-guided TAP Blocks for Open Inguinal Hernia Repair

NCT01589796
View directory record Official record
Conditions
Abdominal Muscles/Ultrasonography, Adult, Ambulatory Surgical Procedures, Anesthetics, Local/Administration & Dosage, Ropivacaine/Administration & Dosage, Ropivacaine/Analogs & Derivatives, Hernia, Inguinal/Surgery, Humans, Nerve Block/Methods, Pain Measurement/Methods, Pain, Postoperative/Prevention & Control, Ultrasonography, Interventional
Interventions
TAP block
Procedure
Lead sponsor
Stamford Anesthesiology Services, PC
Other
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
2
States / cities
Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated May 2, 2012 · Synced Oct 25, 2026, 10:08 AM EDT
Not yet recruiting Phase 4 Interventional

Continuous Delivery of Ranibizumab Via the Port Delivery System for Proliferative Diabetic Retinopathy-related Vitreous Hemorrhage With Pars Plana Vitrectomy and Limited PRP.

NCT07864480
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy, Diabetic Retinopathy, Diabetes
Interventions
PDS Implant filled with 100 mg/mL Ranibizumab, Ranibizumab
Device · Drug
Lead sponsor
Southeast Retina Center, Georgia
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 25, 2026, 10:08 AM EDT